Medtech innovator Xyall attracts €6M Series B funding to further expand its molecular pathology solutions and make them available to the market on a larger scale. The funding comes from existing investors such as the Brabant Development Agency (BOM) and Sioux Technologies, a consortium led by Health Investment Partners (HIP) and several private investors.
Sioux plays an important role in the development and production of the world's first automated high throughput tissue dissector. Xyall's technology enables molecular pathology laboratories to fully automate their workflow for the dissection of tumor tissue and drastically reduce their processing time. The company's first solution, the Tissector High Throughput System, aimed at large molecular laboratories, was launched in 2021. Xyall has since sold several high throughput systems to large, commercial laboratories in the United States, with the first fully operational as of March this year.
The new compact Tissector Table Top System for hospital-based molecular pathology laboratories will be launched in November.
